Doping Status of DHEA Treatment for Female Athletes with Adrenal Insufficiency.

Abstract

OBJECTIVE:

To review the doping status of dehydroepiandrosterone (DHEA) for female athletes with adrenal insufficiency within the framework of Therapeutic Use Exemption (TUE) applications for this proandrogen, which is included on the World Anti-Doping Agency (WADA)'s Prohibited List.

DATA SOURCES AND MAIN RESULTS:

Current knowledge of adrenal pathophysiology with a focus on the physiological role and pharmacological effects of DHEA in female athletes including placebo-controlled clinical trials of DHEA and consensus clinical practice and prescribing guidelines.

CONCLUSIONS:

Because there is no convincing clinical evidence to support the use of DHEA replacement therapy in women with adrenal failure, a TUE for DHEA is not justified by definite health benefit for either secondary or primary adrenal failure. This is consistent with the 2014 update of the US Endocrine Society guidelines, meta-analyses of DHEA treatment in women with or without adrenal failure, current WADA TUE guidance document for adrenal insufficiency and recent case law of WADA's Court of Arbitration for Sport.

• Authors: David J Handelsman, Alvin M Matsumoto, David F Gerrard
• Journal: Clinical journal of sport medicine : official journal of the Canadian Academy of Sport Medicine (Clin J Sport Med) Vol. 27 Issue 1 Pg. 78-85 (Jan 2017) ISSN: 1536-3724 [Electronic] United States
• PMID: 26844622 (Publication Type: Journal Article, Review)

Chemical References

• Dehydroepiandrosterone

Topics

• Adrenal Insufficiency (drug therapy)
• Dehydroepiandrosterone (pharmacology, therapeutic use)
• Doping in Sports (legislation & jurisprudence)
• Female
• Humans